Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Envafolimab Plus Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma, a Prospective, Single Armed Phase II Trial.

Next Previous
Trial Profile

Envafolimab Plus Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma, a Prospective, Single Armed Phase II Trial.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Envafolimab (Primary) ; Cisplatin; Gemcitabine
  • Indications Carcinoma; Nasopharyngeal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 24 Oct 2023 Status changed to active, no longer recruiting, according to Results presented at the 48th European Society for Medical Oncology Congress
  • 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress, All enrolled patients have finished induction chemotherapy treatment, the study is ongoing. Further follow-up is needed to confirm the long-term efficacy. Long-term efficacy is awaited.
  • 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top